Parkinson's Disease
Parkinson's disease is a chronic, neurodegenerative movement disorder caused by the progressive loss of dopamine-producing nerve cells in the substantia nigra of the brain. Its classic features are resting tremor, muscle rigidity and slowness of movement (bradykinesia). In advanced stages where medication becomes insufficient, deep brain stimulation (DBS) is an important surgical option.
Përditësimi i fundit: 2026-06-07
Definition
Parkinson's disease is a progressive neurodegenerative disorder that affects the basal ganglia circuits of the brain. The gradual loss of dopaminergic (dopamine-producing) neurons in the substantia nigra of the midbrain disrupts motor control. Dopamine deficiency produces the classic motor triad: resting tremor, rigidity (muscle stiffness) and bradykinesia (slowness of movement). It is a treatable but, as yet, incurable chronic condition; with appropriate management, symptoms can be controlled for many years.
Causes and Risk Factors
In most cases the exact cause of Parkinson's disease is unknown (idiopathic). Ageing is the strongest risk factor; the disease typically begins between 55 and 65 years of age and is somewhat more common in men than women. About 10-15% of cases involve a familial/genetic predisposition (associated with genes such as LRRK2, PARK2, PINK1 and SNCA). Environmental factors (some pesticides, heavy-metal exposure) and oxidative stress are thought to contribute. Secondary parkinsonism may also develop in relation to certain drugs (particularly some antipsychotics and metoclopramide), repeated head trauma or vascular causes.
Symptoms
Motor symptoms usually begin on one side of the body and spread to the other over years. The main features are resting tremor (a 4-6 Hz tremor that is most evident at rest, especially in the hands), rigidity (muscle stiffness, also called the cogwheel phenomenon), bradykinesia (slowness of movement and reduced facial expression), gait disturbance and, in advanced disease, postural instability (loss of balance and tendency to fall). These may be accompanied by micrographia (small handwriting), hypophonia (a soft voice) and a mask-like facial appearance. Non-motor features that can appear years before motor symptoms include loss of smell, REM sleep behaviour disorder, constipation, depression and, in later stages, cognitive impairment.
Diagnosis
The diagnosis of Parkinson's disease is primarily clinical, based on a detailed history and neurological examination. Diagnosis is supported by the presence of bradykinesia together with at least one of resting tremor or rigidity, and by a clear response to levodopa. Brain MRI is performed to exclude structural causes and other conditions in the differential diagnosis (atypical parkinsonism, vascular parkinsonism, normal-pressure hydrocephalus). A DaTscan (dopamine-transporter SPECT imaging) demonstrates dopaminergic neuron loss and is particularly helpful in distinguishing the condition from essential tremor. The differential diagnosis includes essential tremor, atypical parkinsonian syndromes (MSA, PSP, CBD), drug-induced parkinsonism and normal-pressure hydrocephalus.
Medical (Conservative) Treatment
Medication is the foundation of treatment. Levodopa, a dopamine precursor that is converted to dopamine in the brain, is the most effective drug for motor symptoms and is given with carbidopa or benserazide to reduce peripheral side effects. Dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (selegiline, rasagiline) and COMT inhibitors (entacapone) may be used alone or together with levodopa; amantadine can help reduce dyskinesias. Motor fluctuations (dose-related 'wearing-off' and 'on-off' phenomena) and involuntary movements (dyskinesias) commonly develop within 5-10 years. Supportive therapies such as physiotherapy (balance and gait training), speech therapy and occupational therapy improve quality of life.
Surgical Treatment: Deep Brain Stimulation (DBS)
Deep brain stimulation (DBS) is a surgical option for suitable patients in whom medication has become insufficient and who experience motor fluctuations or troublesome dyskinesias. Thin electrodes are placed into the subthalamic nucleus (STN) or globus pallidus interna (GPi), and a neurostimulator (battery) implanted under the skin of the chest delivers regular electrical stimulation to these targets. DBS does not stop or cure the disease; however, it improves motor fluctuations, reduces dyskinesias and allows a marked reduction in medication dose. Careful candidate selection (a good response to levodopa, absence of severe cognitive impairment or uncontrolled psychiatric illness) strongly influences the outcome. In tremor-dominant cases the VIM nucleus of the thalamus may also be targeted. Atypical parkinsonian syndromes do not respond to DBS.
Prognosis
Although Parkinson's disease is progressive, modern medical therapy and, where appropriate, DBS can control symptoms effectively for many years and preserve quality of life. The course of the disease varies considerably from person to person. A multidisciplinary approach (neurology, neurosurgery, physiotherapy, speech therapy) and regular follow-up provide the best outcomes. The treatment plan is individualized for each patient, and no outcome can be guaranteed in advance.
Burimet
- Greenberg MS. Greenberg's Handbook of Neurosurgery. 10th ed. Thieme; 2023:1840-1841.
- Winn HR, ed. Youmans Neurological Surgery. 6th ed. Saunders; 2011:939-957.
- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
- Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
Ky artikull ka karakter të përgjithshëm informues dhe nuk zëvendëson vizitën mjekësore. Vendimet për diagnozën dhe trajtimin janë individuale.